Antonio Pinero Pilona, MD
Endocrinology, Diabetes & Metabolism · Hudson, FLNPI 1720082068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,987 of the $68,850 with a category attached, or 66.8%. 43 manufacturers reported payments, led by Boehringer Ingelheim at 41.2% of the total. Reporting peaked in 2019 at $31,330 and has fallen 96.4% since, to $1,132 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $154.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$28K
- Lilly USA, LLC$22K
- Novo Nordisk$10K
- Amgen$1K
- Sanofi-aventis U.S. LLC$815
- Medtronic$602
- plus $5K from 37 others
Across 104 payments — averaging $19,205 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.7M
- AbbVie$201K
- Welch Allyn$109K
- Amgen$23K
- Sanofi US Services Inc.$10K
What the payments were for
- Consulting fees$2,9254%
- Speaking & faculty fees$45,98767%
- Travel & lodging$8,77413%
- Food & beverage$11,03916%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,850 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 455 | $745,949 |
| JardianceEmpagliflozin | 369 | $469,120 |
| TrulicityDulaglutide | 140 | $219,679 |
| MounjaroTirzepatide | 135 | $213,165 |
| Tresiba Flextouch U-200Insulin Degludec | 127 | $192,838 |
| RybelsusSemaglutide | 39 | $71,085 |
| FarxigaDapagliflozin Propanediol | 62 | $56,735 |
| ProliaDenosumab | 29 | $50,830 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $42,168 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $41,847 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $38,105 |
| JanuviaSitagliptin Phosphate | 28 | $32,701 |
| SynthroidLevothyroxine Sodium | 303 | $29,332 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $26,878 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $24,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $10,174 | $847,219556 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $28,393 | $508,896402 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev | $22,406 | $451,501337 claims |
| AstraZenecaFarxiga | $400 | $56,73562 claims |
| AmgenProlia | $1,447 | $50,83029 claims |
| MerckJanuvia, Janumet Xr | $153 | $44,81541 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $70 | $11,349957 claims |
| Sanofi-aventis U.S. LLCLantus | $815 | $3,49322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hudson
- Ania JanickaHudson$475K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.